Supplementary Tables 1-3 from Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

Autor: H. Miles Prince, Ricky W. Johnstone, Kenneth Culver, Margaret Dugan, Dale Butterfoss, Peter Atadja, Gail Ryan, Howard Burris, Joachim Beck, Monica Mita, Roxanne Williams-Truax, Chris McCormack, Daniel J. George, Gordon K. Smyth, Yan Pan, Leigh Ellis

Supplementary Tables 1-3 from Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::463e094057a17a83cc864d0e83c33bc3
https://doi.org/10.1158/1078-0432.22439467.v1

Durable Complete Remission and Long-Term Survival in FDG-PET Staged Patients with Stage III Follicular Lymphoma, Treated with Wide-Field Radiation Therapy

Autor: Mathias Bressel, Rodney J. Hicks, H. Miles Prince, Rachel Brown, John F. Seymour, Michael MacManus, Belinda A. Campbell, Max Wolf, Andrew Wirth, Gail Ryan

Publikováno v: Cancers
Volume 12
Issue 4
Cancers, Vol 12, Iss 991, p 991 (2020)

Advanced-stage follicular lymphoma (FL) is generally considered incurable with conventional systemic therapies, but historic series describe long-term disease-free survival in stage III disease treated with wide-field radiation therapy (WFRT), encomp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88ab5f6acaab6dbd2263f3c32b4f8358
https://pubmed.ncbi.nlm.nih.gov/32316464

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial

Autor: Lale Erdem-Eraslan, Roger Stupp, Pim J. French, Th Gorlia, Gail Ryan, Olivier Chinot, F. Dhermain, J.M.M. Gijtenbeek, Monika E. Hegi, P. A. E. Sillevis Smitt, Johan M. Kros, Maaike J. Vos, Carmen Balana, M. Ben Hassel, M. E. van Linde, Gao Y, Khê Hoang-Xuan, A. von Deimling, Brigitta G. Baumert, A. A. Brandes, Bas Weenink, Roelien H. Enting, Warren P. Mason, M. J. van den Bent

Publikováno v: Gao, Y, Weenink, B, van den Bent, M J, Erdem-Eraslan, L, Kros, J M, Sillevis Smitt, P A E, Hoang-Xuan, K, Brandes, A A, Vos, M, Dhermain, F, Enting, R, Ryan, G F, Chinot, O, Ben Hassel, M, van Linde, M E, Mason, W P, Gijtenbeek, J M M, Balana, C, von Deimling, A, Gorlia, T, Stupp, R, Hegi, M E, Baumert, B G & French, P J 2018, ' Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial ', European Journal of Cancer, vol. 94, pp. 168-178 . https://doi.org/10.1016/j.ejca.2018.02.023
European Journal of Cancer
European Journal of Cancer, 2018, 94, pp.168-178. ⟨10.1016/j.ejca.2018.02.023⟩
European Journal of Cancer, 94, 168-178. Elsevier Ltd.
European Journal of Cancer, Elsevier, 2018, 94, pp.168-178. 〈10.1016/j.ejca.2018.02.023〉
European Journal of Cancer, 94, pp. 168-178
European Journal of Cancer, Elsevier, 2018, 94, pp.168-178. ⟨10.1016/j.ejca.2018.02.023⟩
European Journal of Cancer, 94, 168-178
European Journal of Cancer, 94, 168-178. Pergamon
European Journal of Cancer, 94, 168-178. ELSEVIER SCI LTD
European journal of cancer (Oxford, England, 94, 168-178. Elsevier Limited
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Introduction: The European Organisation for Research and Treatment of Cancer (EORTC) 22033-26033 clinical trial (NCT00182819) investigated whether initial temozolomide (TMZ) chemotherapy confers survival advantage compared with radiotherapy (RT) in l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4162fea92c3a37e28fc354eb2873bec4
https://research.vumc.nl/en/publications/58893c65-c797-4e1d-be63-f6fd69c6ec74

Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group

Autor: M. Kuper-Hommel, Pier Luigi Zinzani, Gail Ryan, Richard W. Tsang, L. Santoro, Luca Calabrese, Alessandra Alietti, Sara Steffanoni, Emanuele Zucca, Luca Nassi, Giovanni Martinelli, F. Cavalli, Alphonse G. Taghian, Giancarlo Pruneri, John F. Seymour

Publikováno v: Martinelli, G.; Ryan, G.; Seymour, J. F.; Nassi, L.; Steffanoni, S.; Alietti, A.; Calabrese, L.; Pruneri, G.; Santoro, L.; Kuper-Hommel, M.; Tsang, R.; Zinzani, P. L.; Taghian, A.; Zucca, E.; Cavalli, F. (2009). Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group. Annals of oncology, 20(12), pp. 1993-1999. Oxford University Press 10.1093/annonc/mdp238

Background Primary breast lymphoma (PBL) of low-grade histology is a rare disease. This multicentric retrospective study was carried out to determine clinical features, prognosis and relapse. Patients and methods Patients with histologically proven,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed147f09f5c28ed481bee2abb70bea57
http://doc.rero.ch/record/298701/files/mdp238.pdf

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Autor: Brigitta G. Baumert, Anja Smits, Jacoline E C Bromberg, Christian Borchers, Antje Wick, Michele Reni, Brian Thiessen, Eugenie Verger, Martin J.B. Taphoorn, Roger Stupp, Thierry Gorlia, Guy Kantor, Khê Hoang-Xuan, Michael Back, Warren P. Mason, Roelien H. Enting, Andrew Bottomley, Vassilis Golfinopoulos, Martin Klein, Olivier Chinot, Jaap C. Reijneveld, Alba A. Brandes, Corneel Coens, Peter Hau, Gail Ryan, Mohamed Ben Hassel

Publikováno v: lancet oncology, 17(11), 1533-1542. Lancet Publishing Group
Lancet oncology, 17(11), 1533-1542. Elsevier Science
Lancet Oncology, 17(11), 1533-1542. ELSEVIER SCIENCE INC
The Lancet Oncology, 17(11), 1533-1542
Lancet Oncology, 17(11), 1533-1542. Lancet Publishing Group
Reijneveld, J C, Taphoorn, M J B, Coens, C, Bromberg, J E C, Mason, W P, Hoang-Xuan, K, Ryan, G, Ben Hassel, M, Enting, R H, Brandes, A A, Wick, A, Chinot, O, Reni, M, Kantor, G, Thiessen, B, Klein, M, Verger, E, Borchers, C, Hau, P, Back, M, Smits, A, Nopoulos, V G, Gorlia, T, Bottomley, A, Stupp, R & Baumert, B G 2016, ' Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study ', Lancet Oncology, vol. 17, no. 11, pp. 1533-1542 . https://doi.org/10.1016/S1470-2045(16)30305-9

Summary Background Temozolomide chemotherapy versus radiotherapy in patients with a high-risk low-grade glioma has been shown to have no significant effect on progression-free survival. If these treatments have a different effect on health-related qu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6d3931ec2451bb8d246f7555d002b98
https://pure.amc.nl/en/publications/healthrelated-quality-of-life-in-patients-with-highrisk-lowgrade-glioma-eortc-2203326033-a-randomised-openlabel-phase-3-intergroup-study(1bc982a0-e9c8-4452-9dc1-2a6ed79a22bd).html